Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • Breast Cancer, Metastatic • Breast Cancer, Non-metastatic
If a patient is unable to tolerate one CDK 4/6 inhibitor, do you switch to a different one?
For example, a patient has had multiple dose reductions for neutropenia and required an admission for infection while on palbociclib. Would you switch to abemaciclib?
Answer from: Medical Oncologist at Community Practice
There are currently no data about switching from one CDK 4/6 inhibitor to another. The current recommendations for palbociclib with grade 3 neutropenia and infection are to hold palbociclib until recovery to grade 2 or less and then dose reduce. It sounds as though this patient has required multiple...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I agree. I have had success switching from palbociclib to abemaciclib for patients with neutropenia, and from one CDK4/6 inhibitor to another for a patient with cutaneous toxicity.
Comments
Medical Oncologist at Cleveland Clinic Taussig Cancer Institute
How about if the patient develops pneumonitis from...
How about if the patient develops pneumonitis from...
Answer from: Medical Oncologist at Community Practice
Yes